Filtered By:
Infectious Disease: Pandemics
Vaccination: Veterinary Vaccinations
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1144 results found since Jan 2013.
Preclinical evaluation of a SARS-CoV-2 variant B.1.351-based candidate DNA vaccine
Vaccine. 2023 Sep 17:S0264-410X(23)01091-5. doi: 10.1016/j.vaccine.2023.09.021. Online ahead of print.ABSTRACTThe SARS-CoV-2 pandemic revealed the critical shortfalls of global vaccine availability for emergent pathogens and the need for exploring additional vaccine platforms with rapid update potential in response to new variants. Thus, it remains essential, for the present evolving SARS-CoV-2/Covid-19 and future pandemics, to continuously develop and characterize new and different vaccine platforms. Here, we describe an expression-optimized DNA vaccine candidate based on the SARS-CoV-2 spike protein of the Beta variant (...
Source: Vaccine - September 19, 2023 Category: Allergy & Immunology Authors: Ria Lassauni ère Charlotta Polacek Jeanette Linnea Tingstedt Anders Fomsgaard Source Type: research
Advancements in Nipah virus treatment: Analysis of current progress in vaccines, antivirals, and therapeutics
Immunology. 2023 Sep 15. doi: 10.1111/imm.13695. Online ahead of print.ABSTRACTNipah virus (NiV) causes severe encephalitis in humans. Three NiV strains NiV-Malaysia (NiVM ), NiV Bangladesh (NiVB ), and NiV India (NiVI reported in 2019) have been circulating in South-Asian nations. Sporadic outbreak observed in South-East Asian countries but human to human transmission raises the concern about its pandemic potential. The presence of the viral genome in reservoir bats has further confirmed that NiV has spread to the African and Australian continents. NiV research activities have gained momentum to achieve specific preparedn...
Source: Immunology - September 15, 2023 Category: Allergy & Immunology Authors: Gayatree Mishra Vishal Prajapat Debasis Nayak Source Type: research
The Use of < em > In Silico < /em > Methods to Identify and Assess Antigenic Regions Suitable for the Development of Peptide-based Pan-viral Vaccines
We report a pan-antigenic peptide region with strong affinity for MHC-I and MHC-II, and good immunogenic potential. According to the output from the relevant in silico tools, the peptide was predicted to be non-toxic, non-allergic and to possess the desired physicochemical properties for potentially successful vaccine production. With further investigation and optimisation, this peptide could be considered for use in the development of a broad-spectrum anti-viral vaccine that may protect against emerging new viruses. Our approach of using in silico methods to identify candidate antigenic peptides with the desired physicoch...
Source: Alternatives to Laboratory Animals : ATLA - August 7, 2023 Category: Research Authors: Shayana Saravanakumar Jhinuk Chatterjee Source Type: research
Preclinical evaluation of general toxicity and safety pharmacology of a receptor-binding domain-based COVID-19 subunit vaccine in various animal models
In conclusion, HuVac-19 was not associated with any major systemic adverse effects in the general toxicity and safety pharmacology evaluation, demonstrating that HuVac-19 is a vaccine candidate with sufficient capacity to be used in human clinical trials.PMID:37491472 | DOI:10.1007/s00204-023-03549-6
Source: Archives of Toxicology - July 25, 2023 Category: Toxicology Authors: Sang-Jin Park Min Seong Jang Kwang-Hyun Lim Joung-Wook Seo Wan-Jung Im Kang-Hyun Han Seong-Eun Kim Eunhee Jang Danbi Park Yong-Bum Kim Source Type: research
An overview of anti-SARS-CoV-2 and anti-inflammatory potential of baicalein and its metabolite baicalin: Insights into molecular mechanisms
Eur J Med Chem. 2023 Jul 7;258:115629. doi: 10.1016/j.ejmech.2023.115629. Online ahead of print.ABSTRACTThe current Coronavirus Disease 2019 (COVID-19) pandemic, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is highly contagious infection that breaks the healthcare systems of several countries worldwide. Till to date, no effective antiviral drugs against COVID-19 infection have reached the market, and some repurposed drugs and vaccines are prescribed for the treatment and prevention of this disease. The currently prescribed COVID-19 vaccines are less effective against the newly emergent varian...
Source: European Journal of Medicinal Chemistry - July 12, 2023 Category: Chemistry Authors: Biswanath Dinda Manikarna Dinda Subhajit Dinda Utpal Chandra De Source Type: research
